Document is current
Any future updates will be listed below
-
Authors
Roedl, Kevin https://orcid.org/0000-0002-0721-9027
Ahmadi, Paymon
Essmann, Sonja
Aamir, Sarosh
Haar, Markus
Ayuk, Francis
Karagiannis, Panagiotis
Kröger, Nicolaus
Kluge, Stefan
Wichmann, Dominic
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 19 July 2024
Revised: 29 September 2024
Accepted: 26 November 2024
First Online: 30 December 2024
Declarations
:
: K. Roedl, P. Ahmadi, S. Essmann, S. Aamir, M. Haar, F. Ayuk, P. Karagiannis and N. Kröger declare that they have no competing interests. S. Kluge received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from ADVITOS, Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. D. Wichmann reports personal consultant and lecture fees from 3M, Advanz, AMEOS, Eumedica, EUSA, Gilead, Kite, Lilly, MSD, Novartis, Pfizer and Shionogi.
: The Ethics Committee of the Hamburg Chamber of Physicians was informed about the study (No. 2023-300294-WF). Due to the retrospective nature of the study and the deidentified study data, the need for explicit informed consent was waived. The study was in accordance with the ethical standards of the Ethics Committee of the Hamburg Chamber of Physicians on human experimentation (regional) and with the Helsinki Declaration of 1975, as most recently amended.
